Tatva Chintan Pharma Chem Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/gfuxv5wc0b30woba1h5uu9lh.pdf

Key Takeaways


Margin Destruction: The Q3 Story

Chintan Shah: "It was also kind of a moral responsibility from our part, to kind of absorb. And they have always supported us in our past issues, whenever we had pricing issues, they have been upfront in supporting us. So, now it was a time for us to step up and support them, and we did that."

SDA: Demand Trough and Recovery Bet

Chintan Shah: "We are confident that the volumes in SDAs will rebound strongly from July onwards and we remain optimistic about increasing volumes over the coming years."

New Growth Engines: Electrolyte Salts, Flame Retardants, and Continuous Flow


PASC: A Temporary Air Pocket in a Strong Story

Chintan Shah: "In PASC, we see a very strong demand growing exponentially over the years. So, this is something very difficult to digest, but that is what actually the industry is looking for."

Capacity, Capex, and the Growth Ceiling

Chintan Shah: "Though it is conservative, but it is a very fair estimate to put in place -- and in any case, we will not have enough plant capacities to go beyond that. So, for that, the Greenfield project has to be developed and then only it can take us further beyond INR 900 crores, INR 950 crores revenue."

Guidance & Commitments

CommitmentSpecificsTimeline
RevenueClose FY23 with revenue in excess of ₹400 croreFY23 end
RevenueFlattish growth for next 2 quarters; decent growth next financial yearQ4 FY23 and Q1 FY24; FY24
RevenueReach ₹800-850 crore (constrained by existing capacity)FY25/FY26
EBITDA marginReturn to normal run rate of 22%+Q1 FY24
EBITDA marginQ4 FY23 sees a couple of percentage points gain, but not 22-23%Q4 FY23
SDA demandLarge Chinese customer resumes procurement; strong sales returnMay/June 2023
SDA demandVolumes rebound stronglyJuly 2023 onwards
SDA approvalsApprovals for two new SDAsBy September 2023
Flame retardantsCommercialization beginsQ1 FY24
Electrolyte saltsLarge customer resumes offtakeEnd of June 2023
Electrolyte saltsEnergy storage customer approvals received; good business beginsJuly/August 2023; September 2023 onwards
PASC revenueReturns to ₹40-45 croreH1 FY24
Continuous flow productPlant-scale trial material supplied; commercial supplies beginEnd of August 2023; post April 2024
Pharma intermediateCommercializationEnd of 2024
Greenfield capexDecision to proceedNext couple of quarters
Greenfield constructionCompletion from ground-breaking30 months
Environmental clearanceReceived for greenfield siteBy March 2023
FundraisingEquity dilution to meet 75% public holding and fund greenfieldMid-next year and next few quarters

Key Metrics

MetricQ3 FY23
Revenue from operations₹120.6 cr, +15% YoY
EBITDA₹17.9 cr, -25% YoY
EBITDA margin15%, vs 23% in Q3FY22
PAT₹11.6 cr, -49% YoY
PAT margin10%, vs 22% in Q3FY22
Other income-67% YoY, decline due to lower FD income and absence of ₹2.8 cr forex gain in base quarter
Exports (9MFY23)₹209.5 cr, 70% of revenue
FY23 revenue guidanceIn excess of ₹400 cr, with subdued profitability vs FY22
FY25/FY26 revenue estimateUpward of ₹800 cr to ₹850 cr, constrained by existing infrastructure capacity
PTCs revenue₹32.5 cr, ~35% of total revenue; 9MFY23 growth of 55% YoY
Electrolyte Salts revenue₹4.1 cr, ~5% of total revenue; 9MFY23 growth of 357% YoY
Pharma and Agro Intermediates and Specialty Chemicals revenue₹26.4 cr, ~35% of total revenue; 9MFY23 growth of 36% YoY
SDAs revenue₹57.1 cr, ~24% of total revenue; 9MFY23 decline of 61% YoY
Consolidated inventory₹176.2 cr, down from ₹2,030 cr during the quarter
IPO funds utilized93% (₹192.7 cr of ₹207.28 cr) as on 31 December 2022